NVCR NovoCure Limited
$14.21▼ -1.35%
Healthcare
Other
Volume 21.5K
Avg Volume (10D) 1.50M
Key Metrics & Fundamentals
Market Cap
$1.65B
P/E Ratio
–
Div Yield
0.00%
52W Range
9.82 - 21.45
% vs 50 MA
-10.58%
% vs 200 MA
-2.84%
RSI-14
42.0
MACD Histogram
+0.0800
Beta (1Y vs SPY)
1.57
Free Cash Flow
$1.22M
Gross Rev
$183.58M
Gross Profit
$142.48M
EBITDA
-$6.26M
COGS
$41.11M
Operating Exp
$153.04M
Operating Income
-$10.56M
EBIT
-$10.56M
Pretax Income
-$12.45M
Net Income
-$15.66M
EPS (Diluted)
-0.13
Price & Volume History
Loading chart…
Recent News
The Bull Case For NovoCure (NVCR) Could Change Following Japan’s Optune Pax Pancreatic Cancer Approval
Simply Wall St. · Oct 10, 2026 2:20 AM ET
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Business Wire · Oct 1, 2026 9:00 AM ET
Novocure to Report Third Quarter 2026 Financial Results
Business Wire · Oct 1, 2026 7:00 AM ET
NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall
Simply Wall St. · Sep 23, 2026 1:15 PM ET
NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change
Simply Wall St. · Sep 22, 2026 11:20 PM ET
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
MarketBeat · Sep 18, 2026 10:02 AM ET
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Zacks · Sep 7, 2026 11:12 AM ET
Novocure Announces Upcoming Investor Events
Business Wire · Sep 2, 2026 7:00 AM ET
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Zacks · Aug 28, 2026 9:55 AM ET
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Zacks · Aug 20, 2026 12:00 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See NVCR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.